PDF (Post print) 145085 - Has th...pdf | Document not available for request/download Full text restricted until 21 July 2022.

Abstract

EU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioned their drugs before and after the +1 came into effect. The results show that: i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.

Item Type:	Article
Authors/Creators:	Liddicoat, J and Liddell, K and Aboy, M and Wested, J
Keywords:	drug repurposing, regulatory IP
Journal or Publication Title:	IIC - International Review of Intellectual Property and Competition Law
Publisher:	Springer
ISSN:	2195-0237
DOI / ID Number:	10.17863/CAM.68712
Copyright Information:	Copyright The Author(s) 2021. Post-prints are subject to Springer Nature re-use terms.
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page